| What therapies have replaced rofecoxib in Ireland? | |
| | |
MedLine Citation:
|
PMID: 17555468 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To examine prescription patterns of nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesics in patients prescribed chronic rofecoxib treatment prior to withdrawal from the Irish market, and to determine the impact on proton pump inhibitor (PPI) co-prescription. METHODS: Using a national prescribing database, adults (> or =16 years) prescribed rofecoxib for > or =3 months, but not analgesics, from January to September 2004 were identified. A longitudinal prescribing history was used to determine switching patterns to other cyclooxygenase (COX)-2 inhibitors, NSAIDs or analgesics during 3 and 12 months after withdrawal. Concomitant PPI prescription was examined. Logistic regression was used to determine the likelihood of switching to a COX-2 inhibitor vs. nonselective NSAID and factors influencing concomitant PPI prescription. RESULTS: After rofecoxib withdrawal, 30.2% (1558) and 17.9% (922) of the 5155 study subjects received no further NSAID prescription during 3 and 12 months, respectively. During the 12-month period, approximately one-third of NSAID prescriptions were for <3 months; 40.7% (2096) received sequential prescriptions for different NSAIDs. Co-prescription of analgesics occurred in 49.3% (2539) of subjects. Neither age nor gender influenced the type of NSAID prescribed in the 12 months post rofecoxib withdrawal. PPI prescription increased by 5.5% during the study, associated with use of nonselective NSAIDs, prior use of PPIs and increasing age. CONCLUSIONS: The majority of those receiving chronic rofecoxib therapy were prescribed either no further NSAID or short-term NSAID therapy only during the 12 months post withdrawal, which suggests the subsequent controversy may have encouraged prescribers to adhere more closely to published guidelines. |
| | |
Authors:
|
Mary Teeling; Humphrey O'Connor; John Feely; Kathleen Bennett |
Related Documents
:
|
9773168 - Does post-exercise massage treatment reduce delayed onset muscle soreness? a systematic... 15801488 - Exercise interventions for cancer patients: systematic review of controlled trials. 19332518 - Pre-trial quality assurance processes for an intensity-modulated radiation therapy (imr... 18295688 - N-acetylcysteine use to prevent contrast medium-induced nephropathy: premature phase ii... 2432578 - Clinical experience with an activity sensing pacemaker. 15103438 - Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intra... |
Publication Detail:
|
Type: Journal Article Date: 2007-06-06 |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 64 ISSN: 0306-5251 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-09-20 Completed Date: 2008-03-14 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 536-41 Citation Subset: IM |
Affiliation:
|
Department of Pharmacology and Therapeutics, Trinity College/St James's Hospital, Dublin, Ireland. teelingm@tcd.ie |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anti-Inflammatory Agents, Non-Steroidal / administration & dosage, adverse effects* Cohort Studies Cyclooxygenase 2 Inhibitors / administration & dosage, adverse effects* Drug Prescriptions Drug Utilization / trends* Female Humans Ireland Lactones / administration & dosage, adverse effects* Male Middle Aged Proton Pump Inhibitors / therapeutic use* Sulfones / administration & dosage, adverse effects* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Cyclooxygenase 2 Inhibitors; 0/Lactones; 0/Proton Pump Inhibitors; 0/Sulfones; 0/rofecoxib |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activitie...
Next Document: The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifl...